Navigation Links
FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals' Lead Product Candidate OGX-011
Date:8/22/2008

OGX-011 treatment can significantly reduce serum clusterin levels and that achieving low serum clusterin levels during treatment is correlated with improved survival. Furthermore, serum clusterin levels during OGX-011 treatment may be predictive of a treatment benefit with OGX-011. In patients with HRPC who had failed first-line docetaxel while on or within six months of first-line docetaxel therapy and received second-line chemotherapy in combination with OGX-011 (Study OGX-011-07), achieving or maintaining low serum clusterin levels correlated with improved survival. Similar results were seen in Study OGX-011-05 in patients with NSCLC who were treated with gemcitabine plus a platinum regimen and OGX-011. Data from the Phase 2 study in HRPC were presented at the 2008 Annual Meeting of the American Society of Clinical Oncology.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of specific proteins associated with treatment resistance; OGX-427 and SN2310 are in Phase 1 clinical development; and CSP9222 and OGX-225 are currently in pre-clinical development. More information is available at http://www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning Fast Track Designation for OGX-011 and anticipated clinical and other product development activities and
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GlaxoSmithKline To Post Quarterly US Grants Report
2. FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
3. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
4. US FDA Grants Pediatric Exclusivity for UCBs Keppra(R)
5. Xceed Molecular Grants Gen-Probe License to Xceeds Flow-Thru Chip(R) Technology for Multiplex Molecular Diagnostics
6. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
7. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
8. Lentigen Corporation Receives Four Research Grants From the National Institutes of Health
9. Susan G. Komen for the Cure(R) Announces Largest Grants Slate Ever: $100 Million to Speed Delivery of Breast Cancer Discoveries, Cures
10. European Union, State of Brandenburg, Award Grants to Alcat Europe, GmbH
11. FDA Grants Market Clearance to Aerocrine Inc.s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has announced ... report to their offering. , Global ... data on Trypsin globally and regionally ( Europe ... , Latin America etc.). It ... This report focuses on three primary areas; manufacture methods ...
(Date:2/27/2015)... 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), a ... therapeutics, today announced that it will be presenting at ... March 2 nd at 3pm PST. Patrick Lucy, chief ... discussing the current state of the biosimilar industry landscape ... For more information on CALBIO 2015 and ...
(Date:2/27/2015)... Feb. 27, 2015   PureTech , a science ... commercializing disruptive products and technologies in the healthcare sector, ... former CEO and Member of the Board of Directors ... "It,s has been a pleasure to know Chris ... we will be working together more closely now," said ...
(Date:2/26/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... develops and commercializes proprietary technologies and products for advanced ... for the fiscal first quarter ended December  31, 2014. ... dollars (CAD), unless otherwise stated. "During ... from our existing customers and add to our sales ...
Breaking Biology Technology:Global Market Report of Trypsin 2014-2018 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... reporter cell lines for signal transduction pathway readout ... Alan Greener Mary Buchanan ,John Bauer Chao-Feng ... ,HLR-CREB, HLR-Elk1, and HLR-cJun, cell lines ... that converge at the transcription,factors CREB, Elk1, and c-Jun. ...
... to imitate neurodegeneration , , Rob D. Dickerman ... Walter J. McConathy a,b , a Department of ... Texas Health Science Center , , This article describes ... system cells (hNT Neurons) to imitate the,aging human brain, ...
... high-titer efficiency and larger insert,potential , ... Libraries , Katherine Felts Kim Zaharee ... Peter Vaillancourt ,Stratagene , We introduce ... inserted into the,high-titer retroviral vector pFB. ViraPort ...
Cached Biology Technology:Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion,Transactivators 2Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion,Transactivators 3Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion,Transactivators 4Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion,Transactivators 5Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion,Transactivators 6Sex Steroid Regulation of Vasopressin Levels Secreted by hNT Neurons* 2Sex Steroid Regulation of Vasopressin Levels Secreted by hNT Neurons* 3Sex Steroid Regulation of Vasopressin Levels Secreted by hNT Neurons* 4Sex Steroid Regulation of Vasopressin Levels Secreted by hNT Neurons* 5Sex Steroid Regulation of Vasopressin Levels Secreted by hNT Neurons* 6Sex Steroid Regulation of Vasopressin Levels Secreted by hNT Neurons* 7Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 2Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 3Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 4Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 5Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 6Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 7Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 8Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 9Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 10Functional Cloning Using,ViraPort Retroviral cDNA Expression Libraries 11
(Date:2/19/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/kx9zp8/military ) ... Electro-Optical / Infrared Systems Market by Type, by ... to 2020" report to their offering. ... expected to reach $16.35 billion by 2020, to ... report segments the military electro-optical/infrared systems market on ...
(Date:2/11/2015)... February 11, 2015 ... "Access Control Market by Product (Cards and Readers, Biometrics, ... Defense, Government, Industrial, Healthcare, Education) and By Geography - Global ... MarketsandMarkets, the Access Control Market is expected ... at a CAGR of 10.6% between 2014 ...
(Date:2/5/2015)... 26, 2015   Epic Sciences , a precision diagnostics ... that Murali Prahalad , Ph.D., president and CEO, is ... (PMWC) 2015: Silicon Valley, which is taking place at ... on January 26-28, 2015. Dr. ... as Biomarkers." Last year, Epic Sciences was a finalist in ...
Breaking Biology News(10 mins):Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2
... A. Wells, professor and chairman of the department pharmaceutical ... director of UCSF,s small molecule discovery center, has been ... Biochemistry and Molecular Biology-Merck Award for his pioneering studies ... who also serves on the ASBMB Council, will present ...
... technological innovation with business collaboration to improve conditions for ... new Hunter and Stephanie Hunt Institute for Engineering and ... Gifts totaling $5 million from Hunter and ... B. Lyle and others will establish the institute and ...
... Scientists have designed a synthetic protein that is ... of a native protein, nitric-oxide reductase. , The ... studying nitric-oxide reductase, and for creating biocatalysts for ... Illinois chemistry professor Yi Lu, who directed the ...
Cached Biology News:University of California, San Francisco, researcher receives ASBMB-Merck Award 2New engineering institute to modify, develop technology for the global poor 2New engineering institute to modify, develop technology for the global poor 3Synthetic protein mimics structure, function of metalloprotein in nature 2
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure Grade DAPI is greater than or equal to 98% pure by HPLC....
... Smith et.al. (1997) • Contains ... current biochemistry & molecular biology, ... headwords. Entries give details of ... in which they are involved ...
... • This book describes the basic ... preparing samples for protein transfer and ... bioluminescence-enhanced detection systems are also included. ... and characterization of glycoprotein carbohydrate chains ...
... Walker (1996) • This book offers ... studying proteins and peptides. Each tried ... instruction, timesaving troubleshooting tips, alternative procedures, ... reagents and suppliers. Topics covered range ...
Biology Products: